Sucampo Pharmaceuticals, Inc.
SCMP
SCMP was delisted on the 12th of February, 2018.
136 hedge funds and large institutions have $205M invested in Sucampo Pharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 44 increasing their positions, 51 reducing their positions, and 19 closing their positions.
26% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 19
24% more call options, than puts
Call options by funds: $583K | Put options by funds: $469K
1% more funds holding
Funds holding: 134 → 136 (+2)
7% less capital invested
Capital invested by funds: $220M → $205M (-$15.7M)
14% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 51
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KAM
Krensavage Asset Management
New York
|
+$12M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
+$4.01M |
| 3 |
RA
Royce & Associates
New York
|
+$3.92M |
| 4 |
Renaissance Technologies
New York
|
+$3.16M |
| 5 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
+$2.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.64M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$8.27M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$6.51M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$5.53M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$4.81M |
SCMP Hedge Fund Activity: Q2 2016 in Review
136 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Sucampo Pharmaceuticals, Inc. (SCMP) for Q2 2016, worth a combined $205M — down 7.1% from $220M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new SCMP positions and 19 closed out — a net gain of 5 holders — while 44 added to existing stakes and 51 trimmed.
The largest buyer was Krensavage Asset Management, adding an estimated $12M. The largest seller was Vanguard Group, cutting an estimated $8.64M.
- 136 institutional investors held Sucampo Pharmaceuticals, Inc. (SCMP) as of Q2 2016, up from 134 in Q1 2016.
- Funds reported $205M of Sucampo Pharmaceuticals, Inc. stock for Q2 2016, down 7.1% quarter-over-quarter.
- 24 funds opened new Sucampo Pharmaceuticals, Inc. positions in Q2 2016 and 19 closed out, a net change of +5 holders.
- The largest Sucampo Pharmaceuticals, Inc. buyer in Q2 2016 was Krensavage Asset Management, an estimated $12M added.
- The largest Sucampo Pharmaceuticals, Inc. seller in Q2 2016 was Vanguard Group, an estimated $8.64M sold.
Based on aggregated 13F filings for Q2 2016.